Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Terpos E, Dimopoulos MA, Boccadoro M, Delimpasi S, Beksac M, Katodritou E, Moreau P, Pompa A, Symeonidis A, Bila J, Oriol A, Mateos MV, Einsele H, Orfanidis I, Gries KS, Fastenau J, Liu K, He J, Kampfenkel T, Qiu Y, Amin H, Carson R, Sonneveld P.
Terpos E, et al.
Am J Hematol. 2022 Apr;97(4):481-490. doi: 10.1002/ajh.26480. Epub 2022 Feb 6.
Am J Hematol. 2022.
PMID: 35089607
Free article.